This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
Total Income in Q2 FY25 stood at Rs. 532.18 crore
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Subscribe To Our Newsletter & Stay Updated
